All In Biotech

Drug Trial Radar · NCT03861273

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF-06838435 (RAAV-SPARK100-HFIX-R338L) IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C ≤2%) (BENEGENE-2)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

51

Actual

Start

Jul 29, 2019

Primary completion

Nov 16, 2022

Study completion Feb 25, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce genetic material into cells to compensate for missing or non-functioning Factor IX. Eligible study participants will have completed a minimum 6 months of routine Factor IX prophylaxis therapy during the lead in study (C0371004). Participants will be dosed once (intravenously) and will be evaluated over the course of 6 years. The main objective of the study will evaluate the annualized bleeding rate \[ABR\] for participants treated with gene therapy versus standard of care (SOC) therapy (FIX prophylaxis replacement regimen).

Conditions

  • Hemophilia B

Interventions

  • PF-06838435/ fidanacogene elaparvovecBiological

    Gene Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15Time frame: Pre-infusion period: minimum of 6 months through first dose of current study, an average of 1.31 years (FIX Prophylaxis arm); Week 12 to Month 15 post infusion in current study (PF-06838435 arm)

Locations

65 sites in 16 countries. Site status is shown where the registry gives one.

  • UCSF IDS Pharmacy

    San Francisco, California

  • University of California, San Francisco - Clinical Research Center

    San Francisco, California

  • University of California, San Francisco - Outpatient Hematology Clinic

    San Francisco, California

  • The Regents of the University of California, San Francisco campus

    San Francisco, California

  • Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Regents of the University of Colorado University of Colorado Denver, Office of Grants and Contracts

    Aurora, Colorado

  • Indiana Hemophilia & Thrombosis Center, Inc.

    Indianapolis, Indiana

  • Indiana Hemophilia and Thrombosis Center, Inc

    Indianapolis, Indiana

  • Innovative Hematology, Inc.

    Indianapolis, Indiana

  • St. Vincent Hospital & Health Care Center, Inc.

    Indianapolis, Indiana

  • Madison Radiological Group

    Madison, Mississippi

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Center for Human Phenomic Science

    Philadelphia, Pennsylvania

  • Investigational Drug Service

    Philadelphia, Pennsylvania

  • Penn Blood Disorder Center

    Philadelphia, Pennsylvania

  • The Trustees of the University of Pennsylvania, Office of Clinical Research- Legal

    Philadelphia, Pennsylvania

  • Royal Brisbane and Women's Hospital

    Herston, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO

    Rio de Janeiro, Brazil

  • Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - Hemoes

    Vitória, Espírito Santo, Brazil

  • Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP

    Campinas, São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, São Paulo, Brazil

  • McMaster University Medical Centre - Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Juravinski Hospital - Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Hopital Cardiologique Louis Pradel - CRTH

    Bron, France

  • Hopital Necker

    Paris, France

  • Vivantes Klinikum Friedrichshain

    Berlin, Germany

  • Vivantes Klinikum im Friedrichshain

    Berlin, Germany

  • Universitätsklinikum Bonn Institut für Klinische Chemie und Klinische Pharmakologie -Phase 1-Einheit

    Bonn, Germany

  • Universitätsklinikum Bonn, Anstalt des öffentlichen Rechts

    Bonn, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • General Hospital of Athens "LAIKO", 2nd Regional Blood Transfusion Center

    Athens, Greece

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy

  • Sapporo Tokushukai Hospital

    Sapporo, Hokkaido, Japan

  • Nara Medical University Hospital

    Kashihara, Nara, Japan

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.